Abstract     Description     Claims     Drawing  

US17623808A   [0001] 
US6413245B   [0021] 
US5264188A   [0021] 
US20050244463A   [0021]  [0025] 
US20050244471A   [0025] 
US20050244506A   [0025] 
US395019A   [0025] 
US20050244464A   [0025] 
US20060182781A   [0025] 
US303462A   [0025] 
US11371118B   [0025] 
EP488401A   [0026] 
EP430539A   [0026] 
US56591706A   [0027] 
US742350A   [0029] 
US11859310B   [0029] 
US11952938B   [0029] 
US11364687B   [0029]  [0029] 
US11370301B   [0029] 
US60721600B   [0029] 
US11116698B   [0029] 
US60567423B   [0029] 
US5869079A   [0088] 
US10666872B   [0093] 

Vascular Endothelial Growth Factor Upregulation In Human Central Retinal Vein Occlusion   [0015] 
Effects of topical antiglaucoma medications on the ocular surface   [0020] 
Tear film break up time and Schirmer test after different antiglaucomatous medications   [0020] 
Micropharmaceutics of the eye   [0022] 
Drug delivery to the posterior segment   [0022] 
Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning   [0022] 
Age-related macular degeneration - emerging pathogenetic and therapeutic concepts   [0030] 
New therapeutic targets in atrophic age-related macular degeneration   [0030] 
Vascular Endothelial Growth Factor Gene Polymorphisms in Age-related Macular Degeneration   [0061] 
Age-related macular degeneration: diagnosis and management   [0061] 
Biodegradable Polymers in Controlled Drug Delivery   [0085] 
ARPE-19, a human retinal pigment epithelial cell line with differentiated properties   [0107]